Barclays analyst Peter Lawson lowered the firm’s price target on Immunocore to $66 from $92 and keeps an Overweight rating on the shares. The firm “derisked the model” post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR: